Key Takeaways From Boston Scientific Analyst Ratings
Portfolio Pulse from Benzinga Insights
Boston Scientific (NYSE:BSX) has received a range of analyst ratings over the past three months, with a majority being bullish. Analysts have set a 12-month average price target of $89.31, up from $84.31, with a high estimate of $100.00. Recent analyst actions include several upgrades in ratings and price targets, reflecting positive sentiment. Despite this, Boston Scientific faces challenges with below-industry-average net margin, ROE, and ROA, although it maintains a strong market presence and sound debt management.
October 14, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Boston Scientific has received predominantly bullish analyst ratings, with a 12-month average price target increase to $89.31. Analysts have upgraded their ratings and price targets, indicating positive sentiment. However, the company faces challenges with below-industry net margin, ROE, and ROA.
The majority of analysts have given bullish ratings to Boston Scientific, and the average price target has increased, suggesting a positive short-term outlook. However, the company's financial metrics like net margin, ROE, and ROA are below industry standards, which could pose challenges. The overall sentiment from analysts is positive, which is likely to have a favorable impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100